Recommendations On Use Of Thimerosal Vaccines
In 2003 National Advisory Committee on Immunization published recommendations on the use of vaccines approved for use in Canada that contained the mercury-based preservative thimerosal, so that practitioners would have the necessary information to make sound recommendations for vaccine administration to patients and vaccine manufacturers would have guidance on the future development of vaccines for the Canadian market.
The statement also made recommendations on the management of patients who needed vaccine containing thimerosal but who had reported previous hypersensitivity to this constituent. With the availability of additional evidence on the safety of thimerosal as a preservative in vaccines, NACI published a brief statement updating its recommendations in December 2005 in conjunction with the annual influenza vaccine campaign, promising to follow up with a completely revised statement.
This document should be considered a replacement of both the 2003 and 2005 statements, with new evidence added as appropriate and content from both that is still considered current retained.